Cumulative Exposure to Infliximab, But Not Trough Concentrations, Correlates With Rate of Infection

Infliximab increases the risk of infection in patients with inflammatory bowel diseases (IBD), but there is controversy over the relationship between drug concentration and infections. We aimed to assess factors associated with infection in infliximab-treated patients, including pharmacokinetic features.

Source: Clinical Gastroenterology and Hepatology - March 17, 2020 Category: Gastroenterology Authors: Amandine Landemaine, Antoine Petitcollin, Charl ène Brochard, Céline Miard, Marie Dewitte, Eric Le Balc’h, Thomas Grainville, Eric Bellissant, Laurent Siproudhis, Guillaume Bouguen Source Type: research